15 SEP 2023 | US | Novartis Shareholders Approve Sandoz Spin-Off On 15 September 2023, Novartis shareholders approved...
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Federal Court Shines Light on Patent Litigation Case Management
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 08 Sep 23
08 SEP 2023 | Coherus Completes Acquisition Of Surface Oncology Coherus Biosciences announced that it completed its...
No Anshun Estoppel in Fourth VMS Validity Challenge
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 01 Sep 23
01 SEP 2023 | AU | Celltrion Submits Marketing Application For CT-P43, Biosimilar To Janssen’s Stelara® (Ustekinumab)...
BioBlast w/e 25 Aug 23
25 AUG 2023 | US | Celltrion and J&J Reach Patent Settlement Regarding Ustekinumab Korea Biomedical...
BioBlast w/e 18 Aug 23
18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the...
BioBlast w/e 12 Aug 23
12 AUG 2023 | US | Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023 According to...
Car Park App Scrap Reaches the Merits Stage
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 04 Aug 23
03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that...
BioBlast w/e 28 Jul 23
27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17...
‘Repair’ defence to patent infringement and the perils of hindsight bias
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 21 Jul 23
21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human...
Make priority your priority – ToolGen loses priority battle for CRISPR patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 07 Jul 23
07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its...
Good news for inventors of computer technologies – Perram J redefines manner of manufacture following Aristocrat
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.